Business Context and Reporting Period
Company: Proteon Therapeutics, Inc. (Note: Input metadata referenced "Protara," but the filing identifies the registrant as Proteon Therapeutics, Inc.)
Filing Type: Form 8-K (Current Report)
Date: March 5, 2018
Status: Emerging Growth Company
Context: The filing discloses a material clinical development milestone regarding the Company's investigational drug, vonapanitase.
Key Financial Metrics
This Form 8-K is a current report regarding a specific event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Clinical Milestone: The Company announced the completion of enrollment in PATENCY-2, the second Phase 3 clinical trial of investigational vonapanitase.
- Data Timeline: The Company expects to report top-line data from this trial in March 2019.
Guidance, Outlook, and Risks
Outlook: Management anticipates reporting top-line data for the PATENCY-2 trial in March 2019.
Regulatory Note: The information in this report, including the attached press release (Exhibit 99.1), is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liability of that section, except as expressly set forth by specific reference.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed trial design and patient demographics.
- Confirm the specific definition of "top-line data" expected in March 2019 (e.g., primary endpoint results vs. safety data).
- Review subsequent filings for updates on the PATENCY-2 trial status and any changes to the data release timeline.
- Check the Company's most recent 10-K or 10-Q for current cash runway and burn rate, as this 8-K contains no financial data.